XML 67 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Selected Quarterly Financial Data (Unaudited)
12 Months Ended
Oct. 31, 2014
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data (Unaudited)

(In thousands)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter*
2014
 
 
 
 
 
 
 
Net sales
$
404,980

 
$
412,317

 
$
432,482

 
$
467,997

Gross profit
$
262,929

 
$
268,499

 
$
280,590

 
$
279,552

Income before income taxes
$
79,456

 
$
87,821

 
$
94,383

 
$
34,875

Net income attributable to Cooper stockholders
$
71,843

 
$
79,160

 
$
88,067

 
$
30,787

Earnings per share attributable to Cooper stockholders - basic
$
1.50

 
$
1.65

 
$
1.83

 
$
0.64

Earnings per share attributable to Cooper stockholders - diluted
$
1.47

 
$
1.62

 
$
1.80

 
$
0.63

2013
 
 
 
 
 
 
 
Net sales
$
379,839

 
$
384,041

 
$
411,993

 
$
411,852

Gross profit
$
240,498

 
$
254,179

 
$
268,274

 
$
263,857

Income before income taxes**
$
80,976

 
$
78,940

 
$
91,264

 
$
61,091

Net income attributable to Cooper stockholders
$
74,667

 
$
75,136

 
$
88,951

 
$
57,397

Earnings per share attributable to Cooper stockholders - basic
$
1.54

 
$
1.55

 
$
1.82

 
$
1.18

Earnings per share attributable to Cooper stockholders - diluted
$
1.50

 
$
1.52

 
$
1.79

 
$
1.15



*Fiscal fourth quarter 2014 results include the operating results of Sauflon Pharmaceuticals Ltd., acquired in August 2014, and the related acquisition, integration and restructuring costs. Please refer to Management's Discussion and Analysis of Financial Condition and Results of Operations in Item 7 and Note 2 and Note 3 for additional information.

**Fiscal fourth quarter 2013 results include the $21.1 million loss on divestiture of Aime. See Note 1 for additional information.